標(biāo)題: Titlebook: Diagnoses Without Names; Challenges for Medic Michael D. Lockshin,Mary K. Crow,Medha Barbhaiya Book 2022 Springer Nature Switzerland AG 202 [打印本頁(yè)] 作者: Clinton 時(shí)間: 2025-3-21 17:26
書目名稱Diagnoses Without Names影響因子(影響力)
書目名稱Diagnoses Without Names影響因子(影響力)學(xué)科排名
書目名稱Diagnoses Without Names網(wǎng)絡(luò)公開度
書目名稱Diagnoses Without Names網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Diagnoses Without Names被引頻次
書目名稱Diagnoses Without Names被引頻次學(xué)科排名
書目名稱Diagnoses Without Names年度引用
書目名稱Diagnoses Without Names年度引用學(xué)科排名
書目名稱Diagnoses Without Names讀者反饋
書目名稱Diagnoses Without Names讀者反饋學(xué)科排名
作者: Aspirin 時(shí)間: 2025-3-21 21:56
A Pragmatic Approach to Diagnostic Categorization. Sometimes pragmatic choices need to be made between candidate diagnostic frameworks. Various kinds of diagnostic difficulty are explored, including differences between research and clinical diagnostic categories, “not otherwise specified” categories, and stigmatized diagnoses.作者: 碎石 時(shí)間: 2025-3-22 03:46 作者: 文藝 時(shí)間: 2025-3-22 06:12
Toward Molecular Diagnoses for Autoimmune Rheumatic Diseasesdisorders exhibit extensive clinical and immunologic heterogeneity, and many patients present with evidence of rheumatic diseases but do not fulfill classification criteria, resulting in patient uncertainty and delays in diagnosis and treatment. Several studies have defined distinct molecular signat作者: 可用 時(shí)間: 2025-3-22 09:07 作者: 沉默 時(shí)間: 2025-3-22 14:06
Confronting the Inevitability of Diagnostic Uncertainty Across Multiple Legal Domainsd future course of a particular patient’s ailment posed no great difficulties. As external scrutiny of patient management choices has become commonplace, diagnostic uncertainty poses greater challenges. Although a temptation may exist to visit much of the blame on legal institutions, agencies and co作者: 沉默 時(shí)間: 2025-3-22 17:16 作者: 我不死扛 時(shí)間: 2025-3-22 22:31 作者: 暖昧關(guān)系 時(shí)間: 2025-3-23 03:47
The Impact of Antinuclear Antibody Testing on the Naming and Misnaming of Disease autoimmunity, the antinuclear antibody (ANA) provides information that can be difficult to interpret and, thereby, can contribute to misnaming of certain signs and symptoms as an autoimmune disease, especially systemic lupus erythematosus (SLE). Although a positive ANA test is now considered necess作者: 不感興趣 時(shí)間: 2025-3-23 06:32 作者: 共同生活 時(shí)間: 2025-3-23 13:25
Ever-Evolving Disease Classification Criteria for Clinical Trials and Studies: The Case of Systemic ue patient, classification and classification criteria are used to describe populations for clinical trials and studies and to create somewhat homogeneous, reproducible, and understood populations for clinical research. The development of classification criteria with high sensitivity and specificity作者: 字形刻痕 時(shí)間: 2025-3-23 16:05 作者: FIS 時(shí)間: 2025-3-23 19:28
When the Illness Has No Name: Focus on Clinical Trials in Systemic Lupus Erythematosusrials, especially those with oversight by regulatory agencies, are pure, they are not. Systemic lupus erythematosus (SLE) clinical trials suffer from some of the same issues that plague everyday clinical life. Does everyone in a clinical trial truly have SLE? Is the activity score declared in the ca作者: Slit-Lamp 時(shí)間: 2025-3-23 22:32 作者: nocturnal 時(shí)間: 2025-3-24 06:16
Managing and Tolerating Diagnostic Uncertaintyfor managing diagnostic uncertainty, however, this pursuit is inadequate. Diagnostic knowledge takes time to acquire, and diagnostic uncertainty is not completely curable. Furthermore, diagnostic uncertainty elicits negative psychological responses that need to be palliated, as well as positive resp作者: 針葉類的樹 時(shí)間: 2025-3-24 09:50 作者: Carminative 時(shí)間: 2025-3-24 11:21
In the Box or Out of the Boxtudies in well-defined population. Inclusion and exclusion criteria may be the most important aspect of a clinical study or trial. Lumping or splitting determines which patients can ultimately use a risk stratification algorithm or a therapy. Both processes are valid; studies must be more transparent about how they have lumped or split.作者: 拋棄的貨物 時(shí)間: 2025-3-24 17:54 作者: Ingredient 時(shí)間: 2025-3-24 21:32 作者: 空中 時(shí)間: 2025-3-25 02:09 作者: HERE 時(shí)間: 2025-3-25 06:45 作者: molest 時(shí)間: 2025-3-25 10:18 作者: Customary 時(shí)間: 2025-3-25 12:00
Book 2022ptual or evidentiary boundaries, the person setting the name has a high degree of certainty, and the name has a consensus definition. This book challenges this practice and offers an alternative to assigning diagnoses: quantitating diagnostic uncertainty in personal and public medical plans..This bo作者: AWRY 時(shí)間: 2025-3-25 19:44
Cathleen Grunert,Heinz-Hermann Krügerc risk and molecular pathogenesis can contribute to accurate diagnosis and offer the most appropriate therapy options for a given patient. Recent advances in technology and analytical tools that assess big data now present the possibility of more accurate classification of diseases and pave the way to precision medicine in rheumatology.作者: 拾落穗 時(shí)間: 2025-3-25 22:38 作者: Notorious 時(shí)間: 2025-3-26 01:18 作者: 起皺紋 時(shí)間: 2025-3-26 06:56
Handbuch für Freie Journalistenassifying and managing such patients. Challenges to this approach are considered, notably that, whilst evidence about risk of future outcomes can inform decisions about patient care, it does not remove the uncertainty of the individual patient’s future.作者: 紋章 時(shí)間: 2025-3-26 09:10 作者: 我正派 時(shí)間: 2025-3-26 14:22 作者: 空中 時(shí)間: 2025-3-26 20:52 作者: GENRE 時(shí)間: 2025-3-27 00:32 作者: Mri485 時(shí)間: 2025-3-27 02:35 作者: 極大的痛苦 時(shí)間: 2025-3-27 06:37
Distaler Unterarm, Handgelenk und Handefined categories of recognized illnesses. Indeed, for the sorts of medical questions that administrative officials and judges may need help answering, biomedical researchers and clinicians can offer only limited assistance.作者: 小卒 時(shí)間: 2025-3-27 11:30
https://doi.org/10.1007/978-3-8348-9669-8edications? What has been the impact of improper diagnoses, overstated clinical activity, and medication non-adherence on outcomes of SLE clinical trials? These clinical trial challenges along with solutions are addressed in this chapter.作者: 噱頭 時(shí)間: 2025-3-27 15:04 作者: Obvious 時(shí)間: 2025-3-27 19:45 作者: 一起平行 時(shí)間: 2025-3-27 22:14
Confronting the Inevitability of Diagnostic Uncertainty Across Multiple Legal Domainsefined categories of recognized illnesses. Indeed, for the sorts of medical questions that administrative officials and judges may need help answering, biomedical researchers and clinicians can offer only limited assistance.作者: 健談的人 時(shí)間: 2025-3-28 03:02
When the Illness Has No Name: Focus on Clinical Trials in Systemic Lupus Erythematosusedications? What has been the impact of improper diagnoses, overstated clinical activity, and medication non-adherence on outcomes of SLE clinical trials? These clinical trial challenges along with solutions are addressed in this chapter.作者: Galactogogue 時(shí)間: 2025-3-28 07:58
Managing and Tolerating Diagnostic Uncertainty strategies aimed at helping people tolerate uncertainty. In this chapter, I explore some of these strategies and discuss the meaning of uncertainty tolerance as a guiding goal in the management of diagnostic uncertainty.作者: Fresco 時(shí)間: 2025-3-28 13:24
Michael D. Lockshin,Mary K. Crow,Medha BarbhaiyaExamines the circumstances in which diagnosis names are unassignable.Explores how different stakeholders used diagnosis names for different purposes.Advocates for including diagnostic uncertainty in p作者: osteopath 時(shí)間: 2025-3-28 16:49 作者: PON 時(shí)間: 2025-3-28 19:36
https://doi.org/10.37307/b.978-3-503-20630-8. Sometimes pragmatic choices need to be made between candidate diagnostic frameworks. Various kinds of diagnostic difficulty are explored, including differences between research and clinical diagnostic categories, “not otherwise specified” categories, and stigmatized diagnoses.作者: insidious 時(shí)間: 2025-3-29 02:47 作者: 制定法律 時(shí)間: 2025-3-29 06:29 作者: Comedienne 時(shí)間: 2025-3-29 08:39
Friedrich Rüffler,Robert A. Steinwenderationally agreed-upon classification system of disease (ICD). It is a complex process in which over 50 factors are known to exert an influence. They include individual characteristics of the clinician and their cognitive styles, ambient conditions, ergonomic features of the workplace, the patient an作者: 攀登 時(shí)間: 2025-3-29 13:11 作者: Bricklayer 時(shí)間: 2025-3-29 19:20
Erkrankungen von Leber und Gallenwegen,universe of patients that could benefit from a novel therapy but the majority of patients with shared features of a disease. This framework fits the current model of clinical development and regulatory approval, but it must evolve when studying complex diseases which have multifactorial etiology and作者: 生命層 時(shí)間: 2025-3-29 22:09 作者: PAC 時(shí)間: 2025-3-30 02:49
https://doi.org/10.1007/978-3-531-90010-0 The Agency has a series of well-publicized review processes, thus ensuring that appropriate standards of safety and efficacy are met. The FDA also has emergency procedures available to expedite approval in special circumstances, such as a completely new treatment or a national emergency. The FDA do作者: 和平主義 時(shí)間: 2025-3-30 07:30 作者: 薄膜 時(shí)間: 2025-3-30 09:35
Claus Jürgen Diederichs,Norbert Preu? autoimmunity, the antinuclear antibody (ANA) provides information that can be difficult to interpret and, thereby, can contribute to misnaming of certain signs and symptoms as an autoimmune disease, especially systemic lupus erythematosus (SLE). Although a positive ANA test is now considered necess作者: 玷污 時(shí)間: 2025-3-30 14:37 作者: 準(zhǔn)則 時(shí)間: 2025-3-30 19:06
Bemessung im konstruktiven Betonbau,ue patient, classification and classification criteria are used to describe populations for clinical trials and studies and to create somewhat homogeneous, reproducible, and understood populations for clinical research. The development of classification criteria with high sensitivity and specificity作者: 亂砍 時(shí)間: 2025-3-30 21:28
Handbuch für Freie Journalisten‘what is the evidence that such patients will have a particular outcome at a specified point in the future?’) help to judge the usefulness of a diagnosis and the choice of effective treatments. This chapter focuses on patients with conditions characterised by long-term or recurrent symptoms such as 作者: Iatrogenic 時(shí)間: 2025-3-31 03:53
https://doi.org/10.1007/978-3-8348-9669-8rials, especially those with oversight by regulatory agencies, are pure, they are not. Systemic lupus erythematosus (SLE) clinical trials suffer from some of the same issues that plague everyday clinical life. Does everyone in a clinical trial truly have SLE? Is the activity score declared in the ca作者: Morsel 時(shí)間: 2025-3-31 08:50
Untersuchung der Chromgerbbrühendvanced our understanding across a broad spectrum of disciplines, including chronic autoimmune conditions. As interest and research activity increased in systemic lupus erythematosus (SLE), the fundamental question of “How many people have SLE?” arose. There is tremendous diversity and variability o作者: 訓(xùn)誡 時(shí)間: 2025-3-31 13:03
Untersuchung des Wassers und der Abw?sserfor managing diagnostic uncertainty, however, this pursuit is inadequate. Diagnostic knowledge takes time to acquire, and diagnostic uncertainty is not completely curable. Furthermore, diagnostic uncertainty elicits negative psychological responses that need to be palliated, as well as positive resp作者: Itinerant 時(shí)間: 2025-3-31 13:37
https://doi.org/10.1007/978-3-031-04935-4Clinical trials and diagnostic uncertainty; Diagnoses without names; Diagnostic certainty; Diagnostic t
